Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome : A Randomized Crossover Trial
Amat-Bou, Montse (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Garcia-Ribera, Sonika (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Climent, Eric (Archer Daniels Midland Co-Biopolis, Valencia)
Piquer-Garcia, Irene (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Corripio, Raquel (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Sanchez-Infantes, David (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Villalta, Laia (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Elias, Maria (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Jiménez-Chillarón, Josep C. (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Chenoll, Empar (Archer Daniels Midland Co-Biopolis, Valencia)
Ramón, Daniel (Archer Daniels Midland Co-Biopolis, Valencia, Spain)
Ibáñez, Lourdes (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Ramon-Krauel, Marta (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Lerin, Carles (Hospital Sant Joan de Déu (Barcelona, Catalunya))

Date:	2020
Abstract:	Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1's effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10. 4 years). Participants were randomized to placebo-BPL1 (n = 19) or BPL1-placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4. 5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials. gov NCT03548480).
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Obesity ; Prader-Willi syndrome ; Insulin sensitivity ; Hyperphagia ; Gut microbiota ; Probiotic supplementation ; Mental health
Published in:	Nutrients, Vol. 12 (october 2020) , ISSN 2072-6643

DOI: 10.3390/nu12103123
PMID: 33066107

15 p, 747.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles